How to Reconstitute PT-141 (Bremelanotide): Storage, Stability, and Dosing After Mixing

What Is PT-141 (Bremelanotide) and Why Does Reconstitution Matter?

PT-141, the synthetic melanocortin peptide also called Bremelanotide, acts centrally on melanocortin-3 and melanocortin-4 (MC4R) receptors in the hypothalamus to increase sexual desire. Unlike phosphodiesterase-5 inhibitors, it does not work through vascular mechanisms, so it produces desire rather than erection alone. The FDA approved Bremelanotide (brand name Vyleesi) in June 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women at 1.75 mg subcutaneous per event. 1

Proper reconstitution is not optional technique detail. Peptide bonds in lyophilized powders are stable for months to years under dry, cold conditions, but dissolved peptides degrade through hydrolysis, oxidation, and aggregation. 2 A poorly mixed vial, a wrong diluent, or a warm storage temperature all accelerate that degradation and reduce the dose you actually inject. The steps below follow USP General Chapter <1> sterile compounding principles and published melanocortin peptide stability data.

Mechanism Recap: Why MC4R Agonism Requires Accurate Dosing

Bremelanotide binds MC3R and MC4R with nanomolar affinity. In Phase 3 trials (RECONNECT, N=1,267), the 1.75 mg dose produced statistically significant increases in satisfying sexual events versus placebo (P<0.001) and outperformed lower doses on desire endpoints. 3 Doses above 1.75 mg per event raise nausea incidence sharply (40% at 1.75 mg vs. 61% at 3.5 mg in Phase 2 data), so concentration accuracy directly governs tolerability. 4

Lyophilized Powder vs. The Vyleesi Autoinjector

Compounded lyophilized PT-141 vials require reconstitution by the patient or clinician. The FDA-approved Vyleesi autoinjector arrives pre-filled at 1.75 mg/0.3 mL and needs no mixing. Patients using compounded vials must perform reconstitution themselves, which is why step-by-step precision matters. USP <797> pharmaceutical compounding guidelines classify reconstituted peptide solutions as Category 1 or Category 2 preparations depending on sterility conditions. 5

Supplies You Need Before You Start

Gather every item before breaking the vial seal. Interrupting the process mid-way increases contamination risk and air-bubble introduction.

Required Materials

• Lyophilized PT-141 vial (commonly 10 mg)
• Bacteriostatic water for injection (BWI), 30 mL multi-dose vial
• Two 1 mL insulin syringes with 27 to 31 gauge, 0.5-inch needles
• Two alcohol swabs (70% isopropyl)
• Clean, flat surface (countertop wiped with 70% isopropyl)
• Refrigerator set to 2 to 8 °C

Why Bacteriostatic Water, Not Sterile Water

Bacteriostatic water contains 0.9% benzyl alcohol, a preservative that inhibits microbial growth in multi-dose vials. Sterile water for injection contains no preservative and should only be used for single-dose, immediately administered injections. For a 28-day refrigerated multi-dose vial, benzyl alcohol is the appropriate choice and is standard in compounded peptide protocols. 6 The FDA multi-dose vial guidance confirms benzyl alcohol at 0.9% is safe for subcutaneous administration in adults at the volumes used for peptide dosing. 7

Do not use normal saline (0.9% NaCl) as the sole diluent for a multi-dose vial. Saline lacks a preservative, and opened vials cannot be safely used across multiple injection events spanning days or weeks. 8

Step-by-Step Reconstitution Protocol

Step 1: Hand Hygiene and Surface Prep

Wash hands with soap for at least 20 seconds. Wipe the work surface with a 70% isopropyl swab and allow it to dry for 30 seconds. This reduces but does not eliminate contamination risk outside a clean room. USP <797> Category 1 preparations require ISO 5 conditions; home reconstitution is a practical compromise that demands maximized surface hygiene. 5

Step 2: Swab Both Vial Tops

Swab the rubber septum of the PT-141 vial and the bacteriostatic water vial with separate 70% isopropyl alcohol swabs. Allow each to air-dry for at least 30 seconds before needle insertion. Wet alcohol on a needle tip can carry alcohol into the vial and affect peptide integrity. 9

Step 3: Draw Bacteriostatic Water

Using the first insulin syringe, draw the target volume of bacteriostatic water. For a 10 mg vial with a target concentration of 5 mg/mL, draw 2.0 mL. Because a 1 mL insulin syringe holds only 1 mL, you will need two separate draws of 1.0 mL each, or use a 3 mL syringe for this step alone if available. Inject each mL slowly down the inside wall of the PT-141 vial. Never shoot the stream directly onto the lyophilized cake. Direct pressure can shear peptide bonds and create aggregates. 10

Step 4: Gentle Swirl, Never Shake

After adding diluent, gently swirl the vial in a circular motion for 15 to 20 seconds. Do not vortex or shake. Agitation introduces air bubbles and mechanical shear forces that accelerate aggregation in peptide solutions. 11 The solution should become completely clear. A cloudy or particulate solution indicates incomplete dissolution or degradation. Discard the vial if particulates persist after 60 seconds of gentle swirling.

Step 5: Inspect Before Use

Hold the vial against a light source. The reconstituted solution should be colorless to pale yellow and free of visible particles. Any visible flakes, cloudiness, or discoloration is grounds for discarding the vial and contacting the compounding pharmacy.

Dosing Calculator: Converting Concentration to Syringe Markings

This framework translates any PT-141 vial size and diluent volume into exact insulin-syringe units, removing the arithmetic error that causes under- or over-dosing.

The Core Formula

Volume to inject (mL) = Desired dose (mg) / Concentration (mg/mL)

| Vial size | BWI added | Concentration | 1.25 mg dose | 1.75 mg dose | |-----------|-----------|---------------|--------------|--------------| | 10 mg | 2.0 mL | 5 mg/mL | 0.25 mL (25 units) | 0.35 mL (35 units) | | 10 mg | 1.0 mL | 10 mg/mL | 0.125 mL (12.5 units) | 0.175 mL (17.5 units) | | 5 mg | 1.0 mL | 5 mg/mL | 0.25 mL (25 units) | 0.35 mL (35 units) | | 5 mg | 2.0 mL | 2.5 mg/mL | 0.50 mL (50 units) | 0.70 mL (70 units) |

On a U-100 insulin syringe, each unit mark = 0.01 mL. So 35 units on that syringe = 0.35 mL, which equals 1.75 mg at 5 mg/mL concentration.

Reading an Insulin Syringe Correctly

A U-100 insulin syringe is calibrated in units where 100 units = 1.0 mL. For peptide dosing, ignore the "units" label and treat each graduation as 0.01 mL. If your vial is 5 mg/mL and your dose is 1.75 mg, draw to the 35-unit line. Double-check by multiplying: 35 units × 0.01 mL/unit = 0.35 mL; 0.35 mL × 5 mg/mL = 1.75 mg. 12

Needle Gauge and Length Selection

A 27 to 29 gauge, 0.5-inch needle is appropriate for subcutaneous injection in the abdomen or outer thigh. Shorter needles (0.3125 inch) work in patients with less subcutaneous tissue. A 31 gauge reduces injection pain but may slow draw time slightly. The RECONNECT Phase 3 trial used a 27 gauge, 0.5-inch needle for subcutaneous delivery of 1.75 mg. 3

Storage and Stability After Reconstitution

Refrigerated Shelf Life

Reconstituted PT-141 in bacteriostatic water should be stored at 2 to 8 °C (36 to 46 °F) and used within 28 days. This timeline reflects the antimicrobial activity window of 0.9% benzyl alcohol in multi-dose vials, which the FDA recognizes as providing adequate preservation for up to 28 days after first puncture under refrigerated conditions. 7 Published melanocortin peptide stability data show that cyclic peptides structurally similar to Bremelanotide retain greater than 95% purity by HPLC at 4 °C for 30 days in buffered aqueous solution. 13

Do Not Freeze Reconstituted Solution

Freezing a reconstituted peptide solution causes ice crystal formation that physically damages peptide structure and can cause irreversible aggregation. 14 The lyophilized (dry) powder may be stored frozen before reconstitution, but once mixed, the vial must never go below 2 °C. If the reconstituted vial freezes accidentally, discard it.

Room Temperature Exposure

Keep reconstituted PT-141 at room temperature (15 to 25 °C) only during the brief period needed to draw your dose. Prolonged room temperature exposure, even 24 hours, can reduce peptide purity by 5 to 10% depending on pH and excipient composition. 15 Return the vial to the refrigerator within 30 minutes of use.

Protecting from Light

Store the vial in its original box or wrap it in foil. UV and visible light photodegrade melanocortin peptides through tryptophan and methionine residue oxidation. 16 Bremelanotide does not contain tryptophan but does have oxidation-susceptible residues; light protection is standard practice for all reconstituted peptides.

Vial Puncture Tracking

Mark the date of first reconstitution on the vial label with a permanent marker. A second mark for the 28-day expiry date prevents confusion. Each subsequent draw should use a fresh, sterile needle. Reusing a needle between injection events introduces skin flora into the vial and defeats the purpose of the benzyl alcohol preservative. 9

Injection Technique for Subcutaneous PT-141

Site Selection and Rotation

The lower abdomen (at least 2 inches from the navel) and outer thigh are the preferred subcutaneous sites. Rotate injection sites with each dose to prevent lipohypertrophy. The Vyleesi prescribing information specifies these same sites, and the RECONNECT trial protocol rotated among four abdominal quadrants. 1

Injection Steps

1. Swab the skin site with a fresh alcohol swab and allow 30 seconds to dry.
2. Pinch approximately 1 inch of skin between thumb and forefinger.
3. Insert the needle at 45 to 90 degrees depending on subcutaneous tissue depth. Use 45 degrees in thin patients to avoid intramuscular injection.
4. Slowly depress the plunger over 5 to 10 seconds.
5. Withdraw the needle smoothly and apply gentle pressure with a clean gauze pad. Do not rub.
6. Dispose of the needle in a sharps container immediately.

Timing Relative to Sexual Activity

The Vyleesi label recommends administering at least 45 minutes before anticipated sexual activity. The onset of effect observed in pharmacokinetic studies is approximately 60 minutes after subcutaneous injection, with peak plasma concentrations at 60 to 90 minutes and a half-life of approximately 2.7 hours. 1 Do not administer more than one dose in 24 hours and no more than one dose per event.

Safety, Contraindications, and Side Effects

Common Adverse Effects

Nausea is the most frequent adverse effect. In RECONNECT (N=1,267), 40.1% of Bremelanotide-treated patients reported nausea versus 1.2% placebo. 3 Flushing occurred in 20.3% and injection site bruising in 13.2%. Nausea typically peaks 30 to 60 minutes post-dose and resolves within 2 hours for most patients.

Transient Blood Pressure Changes

Bremelanotide produces a transient, dose-related increase in blood pressure. Mean systolic BP rises approximately 6 mmHg and mean diastolic BP rises approximately 3 mmHg within 30 minutes of the 1.75 mg dose. 1 The FDA contraindicates Bremelanotide in patients with known cardiovascular disease or uncontrolled hypertension. Patients should not take antihypertensive medications within 12 hours of a dose. 1

Hyperpigmentation

Prolonged use (more than 8 weeks of daily dosing in clinical studies) has produced focal hyperpigmentation of the face, gums, and breasts. At the recommended once-per-event, PRN dosing schedule, hyperpigmentation risk is low. 17 Patients with darker baseline skin tones should discuss this risk with their prescriber.

Drug Interactions

Bremelanotide slows gastric emptying and may reduce oral drug absorption. The FDA label specifically warns against co-administration with naltrexone (risk of reduced naltrexone absorption). 1 Space oral medications by at least 2 hours from Bremelanotide dosing.

Troubleshooting Reconstitution Problems

Powder Did Not Dissolve Fully

If white particles remain after 60 seconds of swirling, do not inject. The lyophilized cake may have degraded due to improper storage before shipment. Contact the compounding pharmacy for a replacement vial. Undissolved peptide aggregates can cause injection site reactions and deliver an inaccurate dose. 10

Solution Appears Cloudy or Discolored

A yellow tint is acceptable. Brown, orange, or visibly turbid solution indicates oxidative degradation. Discard immediately. Oxidized Bremelanotide may generate novel peptide fragments with unknown pharmacology and immunogenicity potential. 16

Air Bubbles in the Syringe

Small air bubbles do not cause clinical harm when injecting subcutaneously (unlike intravenous injection). To minimize them, draw slowly and tap the syringe barrel with a fingernail to float bubbles upward, then gently depress the plunger to expel. Bubbles mostly represent a dose accuracy concern: a syringe with 0.05 mL of air instead of medication delivers 12.5% less than the intended 0.40 mL dose at 5 mg/mL.

Vial Runs Out Earlier Than Expected

If a 10 mg/2 mL vial (5 mg/mL) provides only 1.80 mL of recoverable volume instead of 2.00 mL, dead volume in the vial (approximately 0.10 to 0.20 mL) accounts for this. Plan for 10 to 15% dead volume and order accordingly. Some clinicians recommend a slightly higher reconstitution volume (2.2 mL instead of 2.0 mL) to dilute dead-volume effects while still recovering adequate doses. 12

Lyophilized Powder Storage Before Reconstitution

Unopened lyophilized PT-141 vials should be stored at 2 to 8 °C. Many manufacturers permit short-term room temperature storage (up to 25 °C) for 30 days during shipping. Frozen storage at -20 °C is appropriate for long-term (greater than 6 months) inventory. Once removed from the freezer, allow the vial to equilibrate to room temperature for 30 minutes before reconstitution to prevent condensation from being drawn into the solution. 13

The Endocrine Society's clinical practice guidelines on peptide therapeutics note that lyophilized peptides retain biological activity for 24 months at 2 to 8 °C when properly sealed and moisture-protected. 18 Silica gel desiccant packets shipped with vials are functional indicators; a pink desiccant packet (exhausted) signals the vial may have been exposed to humidity.

Regulatory and Compounding Context

Vyleesi (Bremelanotide) holds FDA approval for premenopausal women with acquired, generalized HSDD. Compounded Bremelanotide is used off-label for men and postmenopausal women; these uses fall outside the FDA-approved indication. 1 Compounded preparations must originate from an FDA-registered 503A or 503B facility. The FDA's guidance on compounded drug products requires that 503B outsourcing facilities test finished preparations for sterility, endotoxins, and potency before release. 19

The American Urological Association's sexual medicine guidelines acknowledge Bremelanotide as an evidence-based option for HSDD but stop short of recommending compounded formulations without proof of bioequivalence. 20 Patients and prescribers should verify that any compounding pharmacy holds current PCAB accreditation or equivalent state-level licensure.